Rituximab

Results: 190



#Item
131Cimzia(ß (certolizumab pegol) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIAQ!  safely and effectively. See full prescribing information for CIMZIA.

Cimzia(ß (certolizumab pegol) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIAQ! safely and effectively. See full prescribing information for CIMZIA.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-08-10 12:14:51
132HIGHLIGHTS OF PRESCRIBING INFORMATION   These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-08-31 14:12:04
133Providing Affordable Treatment: Biosimilar Agents Dae Hyun Yoo, M.D.  Rheumatology and Internal Medicine

Providing Affordable Treatment: Biosimilar Agents Dae Hyun Yoo, M.D. Rheumatology and Internal Medicine

Add to Reading List

Source URL: aplarcongress.org

Language: English - Date: 2014-04-23 05:34:26
134APLAR 2014, Cebu, April 3, 2014  Rheumatoid Arthritis treatment with biologics  Tsutomu Takeuchi, MD.PhD.

APLAR 2014, Cebu, April 3, 2014 Rheumatoid Arthritis treatment with biologics Tsutomu Takeuchi, MD.PhD.

Add to Reading List

Source URL: aplarcongress.org

Language: English - Date: 2014-04-23 05:32:38
135

PDF Document

Add to Reading List

Source URL: aplarcongress.org

Language: English - Date: 2014-03-27 11:16:24
136Clinical Practice Guideline

Clinical Practice Guideline

Add to Reading List

Source URL: www.albertahealthservices.ca

Language: English - Date: 2013-03-05 15:53:51
137Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) Safety Announcement[removed]The U.S. F

Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) Safety Announcement[removed]The U.S. F

Add to Reading List

Source URL: www.fda.gov

Language: English
138DSQ Drug Safety Quarterly Vo l[removed]Wi n te r[removed]

DSQ Drug Safety Quarterly Vo l[removed]Wi n te r[removed]

Add to Reading List

Source URL: www.rheumatology.org

Language: English
139DSQ Drug Safety Quarterly Vo l[removed]No v e m b e r[removed]

DSQ Drug Safety Quarterly Vo l[removed]No v e m b e r[removed]

Add to Reading List

Source URL: www.rheumatology.org

Language: English
140DSQ Drug Safety Quarterly Vo l[removed]Sp ri n g[removed]

DSQ Drug Safety Quarterly Vo l[removed]Sp ri n g[removed]

Add to Reading List

Source URL: www.rheumatology.org

Language: English